---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009313"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:13:37.482659+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PTC518 Ph2 PIVOT-HD shows mHTT lowering and clinical trends; FDA lifts partial clinical hold

## Summary
- PTC518 lowered mHTT in blood by 22% (5mg) and 43% (10mg) at Month 12; similar CSF levels.
- Total Motor Score worsening: 2.0 (5mg), 1.3 (10mg) vs 4.9 for placebo, suggesting slowed progression.
- FDA lifted partial clinical hold on PTC518 program based on PIVOT-HD interim data.
- Company received $250M from Royalty Pharma for first tranche of Evrysdi royalty sale under amended agreement.
- Hopewell lease amended to significantly reduce space and rent; lease no longer considered material.

## SEC filing metadata
- accession: 0001558370-24-009313
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000155837024009313/0001558370-24-009313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000155837024009313/tmb-20240617x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009313
- JSON: https://secwatch.observer/filing/0001558370-24-009313.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009313.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.